lung cancer
Conditions
Interventions
Preoperative TACE combined with fluorescence detection group: TACE+fluorescence detection
Fluorescence detection group:Fluorescence detection
surgery alone group:Surgery
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients in good general condition with Eastern Cooperative Oncology Group (ECOG) score 0-2, good cardiopulmonary function, and can tolerate adjuvant DEB-TACE treatment and surgical resection. 2. Those with pre-surgical resection liver function of Child-A grade or liver function of Child-B grade up to Chi-Ld-A grade after treatment with liver protection and nutritional rehydration. 3. Before pre-operative adjuvant DEB-TACE treatment or surgical resection, liver tumors were proven to be =10.0 cm in diameter by B ultrasound, MRI or CT plain + enhanced examination, giant mass type, and the liver tumors were located in the hemihepatic or confined within the three adjacent hepatic lobes. 4. In addition to the hepatic tumor, the remaining liver volume is tolerated by 3D visualization measurement for lobectomy (i.e.: the remaining liver volume is greater than 40% of the standard liver volume); liver reserve function measurement 72 hours prior to surgical resection suggests: indocyanine chloride 15-minute retention rate <10%. 5. Preoperative imaging data suggesting no portal vein trunk cancer thrombus. 6. Preoperative assessment of no local or distant lymph node metastasis of the tumor and no extrahepatic metastasis. 7. Patients were informed in detail of the possible advantages and disadvantages of preoperative and postoperative DEB-TACE, and patients and their families chose the treatment option voluntarily.
Exclusion criteria
Exclusion criteria: 1. Patients with recurrent hepatocellular carcinoma or previously treated with liver transplantation, ablation or external radiation, PVE, hepatic artery ligation, etc. 2. Patients treated with DEB-TACE only. 3. Patients with concurrent or previous other malignancies. 4. Patients with a history of allergy to iodine agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Surgical resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of postoperative complications;Postoperative recurrence rate; | — |
Countries
China
Contacts
Public ContactBo Li
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed